| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ... New England Journal of Medicine 351 (15), 1502-1512, 2004 | 7396 | 2004 |
| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5360 | 2012 |
| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5158 | 2011 |
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2369 | 2009 |
| Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ... New England Journal of Medicine 377 (4), 352-360, 2017 | 2263 | 2017 |
| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 1953 | 2020 |
| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1768 | 2021 |
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1747 | 2012 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1450 | 2016 |
| Apalutamide for metastatic, castration-sensitive prostate cancer KN Chi, N Agarwal, A Bjartell, BH Chung, AJ Pereira de Santana Gomes, ... New England Journal of Medicine 381 (1), 13-24, 2019 | 1389 | 2019 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1383 | 2019 |
| Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a … K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ... The Lancet Oncology 20 (5), 686-700, 2019 | 768 | 2019 |
| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 703 | 2018 |
| Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ... Journal of Clinical Oncology 36 (24), 2492-2503, 2018 | 683 | 2018 |
| Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 682 | 2020 |
| Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ... Clinical cancer research 21 (10), 2315-2324, 2015 | 530 | 2015 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 494 | 2018 |
| Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ... Journal of clinical oncology 34 (14), 1652-1659, 2016 | 454 | 2016 |
| Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ... JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017 | 407 | 2017 |
| Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study KN Chi, S Chowdhury, A Bjartell, BH Chung, ... Journal of Clinical Oncology 39 (20), 2294-2303, 2021 | 399 | 2021 |
Arun AzadAssociate Professor & Medical Oncologist, Peter MacCallum Cancer CentreVerified email at monash.edu
